Lack of effect of chronic developmental lead treatment on biogenic amines and metabolites in monkey cerebrospinal fluid.
Concentrations of 3,4 dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), norepinephrine (NE), 3-methoxy-4-hydroxyphenylglycol (MHPG), and 5-hydroxyindoleacetic acid (5-HIAA) were assayed in the cerebrospinal fluid (CSF) of control and chronically lead-treated nursery-reared rhesus monkeys sampled periodically from infancy through adulthood. Blood lead levels peaked at 62 micrograms/dl at 1.5 months of age, averaged 45 micrograms/dl for the remainder of the first year postpartum, and were maintained at 14 micrograms/dl from 20-58 months of age. Cisternal CSF samples were collected monthly from 5-35 months of age and every 1-4 months from 36-58 months of age. Biogenic amine and metabolite concentrations were assayed by high-performance liquid chromatography with electrochemical detection. Overall concentrations of DOPAC, HVA, NE, MHPG, and 5-HIAA were not significantly different in the control and lead-treated groups nor were there any significant interactions between lead treatment and age for any measure. DOPAC, HVA, and 5-HIAA concentrations decreased gradually with age, whereas MHPG concentration decreased sharply between 35 and 40 months of age. NE concentration remained stable across development.
Ferguson
S A
SA
Harlow Primate Laboratory, University of Wisconsin, Madison 53715.
Kraemer
G W
GW
Bowman
R E
RE
Schmidt
D E
DE
Ebert
M H
MH
D000375:Aging / Q000134:cerebrospinal fluid; D000818:Animals; D001679:Biogenic Amines / Q000134:cerebrospinal fluid*; D002851:Chromatography, High Pressure Liquid; D004563:Electrochemistry; D005260:Female; D007854:Lead / Q000097:blood / Q000633:toxicity*; D008253:Macaca mulatta; D008297:Male; D011597:Psychomotor Performance / Q000187:drug effects
D001679:Biogenic Amines; D007854:Lead